Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

BACKGROUND: We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel. METHODS: Circulating pro/anti-angiogenic factors were assessed on day 1 (D1) and day 8 (D8). The prognostic value for progression-free survival (PFS) w...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Cancer
Asıl Yazarlar: Lebellec, Loïc, Bertucci, François, Tresch-Bruneel, Emmanuelle, Ray-Coquard, Isabelle, Le Cesne, Axel, Bompas, Emmanuelle, Blay, Jean-Yves, Italiano, Antoine, Mir, Olivier, Ryckewaert, Thomas, Toiron, Yves, Camoin, Luc, Goncalves, Anthony, Penel, Nicolas, Le Deley, Marie-Cécile
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2018
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6180490/
https://ncbi.nlm.nih.gov/pubmed/30305054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4828-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller